Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Hurthle Cell Thyroid Neoplasia: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Hurthle Cell Thyroid Neoplasia: 1 US clinical trial tracked, none currently recruiting.

Hurthle Cell Thyroid Neoplasia is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition hurthle-cell-thyroid-neoplasia

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Hurthle Cell Thyroid Neo (th…0%
Open-enrollment share among volume-matched conditions near Hurthle Cell Thyroid Neoplasia

Hurthle Cell Thyroid Neoplasia has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hurthle Cell Thyroid Neoplasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hurthle Cell Thyroid Neoplasia is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Hurthle Cell Thyroid Neoplasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PDR001 Drug
1 trials
Dabrafenib Drug
1 trials
Trametinib Drug
1 trials

US sites by state

Facility locations filed on Hurthle Cell Thyroid Neoplasia trials. A trial with sites in several states counts in each.

New York 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hurthle Cell Thyroid Neoplasia page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Hurthle Cell Thyroid Neoplasia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Memorial Sloan Kettering Cancer Center sponsors the most Hurthle Cell Thyroid Neoplasia trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hurthle Cell Thyroid Neoplasia condition card totals 1 registered trials; most-linked intervention PDR001; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.